IP Library Patent Application 15140109
Patent Application
App. No. 15/140,109

TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/140,109
Abstract

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

Claims (12)

1 . A topical pharmaceutical composition comprising:

about 5% w/w to about 10% w/w dapsone;

about 0.1% w/w to about 0.3% adapalene;

about 30% w/w to about 40% w/w diethylene glycol monoethyl ether;

about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and water.

2 . The composition of claim 1 , wherein the dapsone is present at a concentration of about 10% w/w.

3 . The composition of claim 2 , wherein the adapalene is present at a concentration of about 0.1% w/w.

4 . The composition of claim 3 , wherein the diethylene glycol monoethyl ether is present at a concentration of about 35% w/w.

5 . The composition of claim 3 , wherein the diethylene glycol monoethyl ether is present at a concentration of about 40% w/w.

6 . The composition of claim 1 , wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.

7 . The composition of claim 1 , wherein the topical pharmaceutical composition further comprises methyl paraben.

8 . The composition of claim 1 , wherein the topical pharmaceutical composition further comprises EDTA.

Assignments (8)
ASSIGNEE CHANGE OF ADDRESS Recorded Sep 11, 2023
From: ALMIRALL, LLC
To: ALMIRALL, LLC
Reel/Frame 064858/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: ALLERGAN, INC.
To: ALMIRALL, LLC
Reel/Frame 047132/0642 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: WARNER, KEVIN S.; PARASHAR, AJAY P.
To: ALLERGAN, INC.
Reel/Frame 038398/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: BHATT, VARSHA; SWAMINATHAN, VIJAYA
To: DOW PHARMACEUTICAL SCIENCES
Reel/Frame 038398/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: DOW PHARMACEUTICAL SCIENCES
To: ALLERGAN, INC.
Reel/Frame 038398/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: PARASHAR, AJAY P.; WARNER, KEVIN S.
To: ALLERGAN, INC.
Reel/Frame 038398/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: BHATT, VARSHA; SWAMINATHAN, VIJAYA
To: DOW PHARMACEUTICAL SCIENCES
Reel/Frame 038398/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2016
From: DOW PHARMACEUTICAL SCIENCES
To: ALLERGAN, INC.
Reel/Frame 038398/0560 →